Brawn Biotech Ltd
Incorporated in 1985, Brawn Biotech Ltd is in the business of trading pharmaceutical products[1]
- Market Cap ₹ 6.32 Cr.
- Current Price ₹ 21.0
- High / Low ₹ 24.4 / 16.2
- Stock P/E 48.6
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding has decreased over last quarter: -0.45%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| 0.48 | |
| 0.49 | |
| Operating Profit | -0.01 |
| OPM % | -2.08% |
| 0.24 | |
| Interest | 0.00 |
| Depreciation | 0.01 |
| Profit before tax | 0.22 |
| Tax % | 18.18% |
| 0.19 | |
| EPS in Rs | 0.63 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -8% |
| 3 Years: | 9% |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Net Cash Flow | |
| Free Cash Flow | |
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Permanent Employees Count ・Standalone data |
|
|||||
| Trade Receivable Turnover Ratio Times ・Standalone data |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Newspaper publication of Audited Financial Results for Quarter and Year ended 31.03.2026
-
Intimation Regarding Non-Applicability Of Regulation 23(9)
30 May - Brawn Biotech says RPT disclosure under Regulation 23(9) is not applicable for year ended March 31, 2026.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Brawn Biotech says annual secretarial compliance report not applicable as of 31 Mar 2026.
-
Results- Financial Results For Year Ended 31St March 2026
29 May - Board approved audited Q4 and FY2026 results on 29 May 2026; auditors issued unmodified opinion.
-
Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On 29Th May 2026, And Submissions Of Audited Financial Results For The Quarter And Year Ended 31.03.2026
29 May - Board approved audited FY26 results; revenue 1,743.18 lakh, PAT 94.06 lakh, unmodified audit opinion.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
BBL is a fully integrated healthcare company that deals in pharmaceutical products, covering segments:
a) Antibacterial
b) Cardiovascular
c) Antidiabetics
d) Analgesics
e) Gastrointestinal
f) Antifungals
g) Skin Care
h) Antipsychotics,
i) Anti-asthmatics
j) Antacids
k) Antimalarial
l) Nutritional